Calidi Biotherapeutics, Inc. (CLDI) stock
CLDINYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as CLDWW
$0.53−0.03 (-5.79%)
Close on Nov 18, 2026Market cap $1.36MP/E –Yield –
Calidi Biotherapeutics net income
Net income is the profit left for shareholders after every expense, interest and tax.
Calidi Biotherapeutics's net income for the twelve months ending Jun 30, 2026 was -$17.47M. For fiscal 2025 it was -$19.91M.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$19.91M | – |
| FY2024 | Dec 31, 2024 | -$22.14M | – |
| FY2023 | Dec 31, 2023 | -$29.22M | – |
| FY2022 | Dec 31, 2022 | -$25.43M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.16M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.11M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.06M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.15M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.72M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.99M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.10M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.05M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.77M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.23M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.23M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.02M | – |
| Q2 FY2023 | Jun 30, 2023 | -$12.50M | – |
| Q1 FY2023 | Mar 31, 2023 | -$6.46M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.76M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.36M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.58M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.74M | – |
| Q3 FY2021 | Sep 30, 2021 | -$823.29K | – |
| Q2 FY2021 | Jun 30, 2021 | -$83.30K | – |
See a number that looks wrong?